menu search

NUVB / FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET family that epigenetically regulates proteins that control tumor growth and differentiation. Read More
Posted: Jan 20 2022, 08:43
Author Name: Benzinga
Views: 102951

NUVB News  

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

By Zacks Investment Research
January 21, 2022

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types f more_horizontal

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

By Zacks Investment Research
January 21, 2022

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types f more_horizontal

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

By Zacks Investment Research
January 21, 2022

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types f more_horizontal

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

By Benzinga
January 20, 2022

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumor more_horizontal

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

By Benzinga
January 20, 2022

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumor more_horizontal

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

By Benzinga
January 20, 2022

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumor more_horizontal


Search within

Pages Search Results: